COSCIENS BIOPHARMA INC(CSCIF.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
COSCIENS BIOPHARMA INC
CSCIF.US
1.883 T
CSCIF.USMarket value -Rank by Market Cap -/-

Financial Score

21/01/2026 Update
D
BiotechnologyIndustry
Industry Ranking327/398
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-118.80%E
    • Profit Margin-164.63%E
    • Gross Margin36.75%C
  • Growth ScoreD
    • Revenue YoY-3.97%D
    • Net Profit YoY-120.08%E
    • Total Assets YoY-45.49%E
    • Net Assets YoY-74.62%E
  • Cash ScoreD
    • Cash Flow Margin-60.74%D
    • OCF YoY-3.97%D
  • Operating ScoreD
    • Turnover0.27D
  • Debt ScoreE
    • Gearing Ratio78.71%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Cosciens Biopharma Signs Exclusive Macrilen Distribution Deal with Wuzhou Drug International

    Cosciens Biopharma's subsidiary, Aeterna Zentaris GmbH, signed an exclusive distribution agreement with Wuzhou Drug International for Macrilen® in Hong Kong, Macao, Singapore, and parts of China. Wuzhou will manage registration, importation, and commercialization, with a ten-year term and an initial order of €800,000. The news was published by Cosciens Biopharma via GlobeNewswire.

    Reuters·
    US
    CSCI
    0.00%
    Reuters·
    US
    CSCI
    0.00%

    COSCIENS Biopharma Appoints Peter H. Puccetti as Interim CEO

    07:44 AM EST, 11/17/2025 (MT Newswires) -- COSCIENS Biopharma ( CSCIF ) , which rose 3.15% on Friday, announced over the weekend that the chairman of its board of directors, Peter H. Puccetti, has been appointed as the company's interim chief executive, effective immediately.Puccetti expands his role with this appointment and succeeds Anna Biehn, who has stepped down as CEO.Shares of the company were last seen up $0.1 to $3.3 on Friday on the Toronto Stock Exchange. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

    fidelity·
    US
    CSCI
    0.00%
    US
    CSCIF
    0.00%
    fidelity·
    US
    CSCI
    0.00%
    US
    CSCIF
    0.00%

    Cosciens Biopharma Appoints Peter Puccetti as Interim CEO

    Cosciens Biopharma Inc. has appointed Peter H. Puccetti as Interim CEO, replacing Anna Biehn. This leadership change is part of the company's efforts to strengthen operations and align with strategic priorities. The announcement was made on November 14, 2025, via GlobeNewswire.

    Reuters·
    US
    CSCI
    0.00%
    US
    CSCIF
    0.00%
    Reuters·
    US
    CSCI
    0.00%
    US
    CSCIF
    0.00%

    COSCIENS Biopharma Reports Q3 2025 Financial Results

    Cosciens Biopharma Inc. (CSCIF) reported its Q3 2025 financial results, showing a consolidated net loss of $1.8 million, an improvement from $5.8 million in Q3 2024. The company has delisted from Nasdaq but remains on the Toronto Stock Exchange. Total revenue decreased to $1.5 million, down from $1.9 million, due to reduced sales. Strategic initiatives include suspending the Juvente Cosmeceuticals line and focusing on expanding active ingredients into new markets. COSCIENS aims to enhance operational efficiency and explore partnerships in the U.S. market.

    Tip Ranks·
    US
    CSCIF
    0.00%
    Tip Ranks·
    US
    CSCIF
    0.00%

    Cosciens Biopharma Inc. posts $1.7 million revenue and $5.9 million net loss for Q3 2025

    Cosciens Biopharma Inc. reported Q3 2025 revenue of $1.7 million, a significant increase from $0.2 million in the same period last year. The company incurred a net loss of $5.9 million, with research and development expenses decreasing to $0.6 million. Cash and cash equivalents were $8.5 million as of September 30, 2025, down from $16.4 million at the end of 2024. The company continues to develop products in the cosmeceutical, nutraceutical, and pharmaceutical sectors using its PGX technology.

    Reuters·
    US
    CSCIF
    0.00%
    Reuters·
    US
    CSCIF
    0.00%
    © 2026 Longbridge｜Disclaimer